AUSPERBIO
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
AUSPERBIO
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2019-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.ausperbio.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
50.67 M USD
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
EpiVario
EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
VintaBio
VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.
Investors List
BioVenture
BioVenture investment in Series A - AusperBio
Genesis Capital
Genesis Capital investment in Series A - AusperBio
InnoPinnacle Fund
InnoPinnacle Fund investment in Series A - AusperBio
Qiming Venture Partners
Qiming Venture Partners investment in Series A - AusperBio
Hankang Capital
Hankang Capital investment in Series A - AusperBio
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-03 | AusperBio Welcomes Dr. Will Wei as Head of CMC |
Official Site Inspections
http://www.ausperbio.com
- Host name: 8.208.94.211
- IP address: 8.208.94.211
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "AusperBio"
AusperBio - Crunchbase Company Profile & Funding
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their …See details»
AusperBio - LinkedIn
AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative …See details»
AusperBio Company Profile | Management and Employees List
AusperBio Profile and History. AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. …See details»
AusperBio - Overview, News & Similar companies | ZoomInfo.com
Dec 26, 2024 AusperBio. Business Services · California, United States · 80 Employees. View Company Info for Free . About. Headquarters 3 E 3rd Ave Ste 200, San Mateo, California, …See details»
AusperBio Company Profile - Office Locations, Competitors ... - Craft
AusperBio is a biopharmaceutical company that develops therapies for hepatitis B (HBV) treatment. It offers Med-Oligo ASO, a technology platform that enhances antisense …See details»
Org Chart AusperBio - The Official Board
Organizational Chart of AusperBio. AusperBio www.ausperbio.com +1 650 888 1756; Add an executive. AusperBio News . Anything missing? We search for you. Print or download . Board. …See details»
AusperBio Company Profile 2025: Valuation, Funding & Investors
AusperBio General Information Description. Provider and developer of small interfering ribonucleic acid (siRNA) drugs designed for hepatitis B. The company focuses on innovative treatments …See details»
AusperBio - Products, Competitors, Financials, Employees, …
AusperBio is a clinical-stage biotechnology company focused on developing oligonucleotide therapies for treating chronic hepatitis B. The company's main offerings include a proprietary …See details»
Ausperbio Therapeutics Inc. Company Profile | San Mateo, CA ...
Find company research, competitor information, contact details & financial data for Ausperbio Therapeutics Inc. of San Mateo, CA. Get the latest business insights from Dun & Bradstreet.See details»
AusperBio - Funding, Financials, Valuation & Investors - Crunchbase
AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases. Search Crunchbase. ... How much funding has this …See details»
Ausperbio
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and …See details»
Organigramme AusperBio - The Official Board
Organizational Chart of AusperBio. AusperBio www.ausperbio.com +1 650 888 1756; Ajouter un décideur. AusperBio Actualités . Un manquant? Nous le cherchons. Imprimer ou télécharger . …See details»
Ausper Biopharma Co., Ltd. - Drug pipelines, Patents ... - Patsnap
Nov 22, 2024 SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology …See details»
AusperBio Secures $73 Million in Series B Financing to Advance ...
Dec 26, 2024 AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing …See details»
AusperBio - Crunchbase
AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases. ... Solutions. Products. Resources. Pricing. Resources. …See details»
AusperBio Secures $73 Million in Series B Financing to Advance ...
SAN FRANCISCO, Dec. 26, 2024 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology …See details»
AusperBio secures funding to advance AHB-137 for CHB
Jul 15, 2024 AusperBio has raised $37m in a Series A financing round to propel the clinical development of AHB-1 for chronic hepatitis B (CHB). The funding round was spearheaded by …See details»
AusperBio Raises $73M in Series B Financing - finsmes.com
Dec 27, 2024 AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a US and China based clinical-stage biotechnology company dedicated to …See details»
AusperBio Raises $37 Million in Series A Round for Antisense ...
Jul 18, 2024 AusperBio, a Hangzhou-San Francisco biotech, completed a $37 million Series A financing. The company develops therapies based on its novel oligonucleotide and targeted …See details»
AusperBio: $73 Million (Series B) Raised To Advance Targeted ...
AusperBio, a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), …See details»